Poly Medicure

how big is Poly Medicure?

As of Jun 06, Poly Medicure Ltd has a market capitalization of 22,655.92 Cr, with recent net sales of 1,669.84 Cr and net profit of 338.55 Cr on a consolidated basis. Shareholder's funds are 1,470.05 Cr, and total assets amount to 1,858.67 Cr as of Mar'24.

Market Cap: As of Jun 06, Poly Medicure Ltd has a market capitalization of 22,655.92 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported a sum of Net Sales of 1,669.84 Cr and a sum of Net Profit of 338.55 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 1,470.05 Cr, while Total Assets amount to 1,858.67 Cr.

Who are in the management team of Poly Medicure?

As of March 2022, the management team of Poly Medicure includes Chairman Devendra Raj Mehta, Managing Director Himanshu Baid, and several non-executive directors, totaling 13 key members who guide the company's governance and strategy.

As of March 2022, the management team of Poly Medicure includes the following individuals:<BR><BR>1. Devendra Raj Mehta - Chairman & Independent Director<BR>2. Jugal Kishore Baid - Non-Executive & Non-Independent Director<BR>3. Prakash Chand Surana - Non-Executive & Independent Director<BR>4. Himanshu Baid - Managing Director & CEO<BR>5. Rishi Baid - Joint Managing Director<BR>6. Shailendra Raj Mehta - Non-Executive & Independent Director<BR>7. Mukulika Baid - Non-Executive & Non-Independent Director<BR>8. Avinash Chandra - Company Secretary & Compliance Officer<BR>9. Sandeep Bhargava - Non-Executive & Independent Director<BR>10. Alessandro Balboni - Non-Executive & Non-Independent Director<BR>11. Amit Khosla - Non-Executive & Independent Director<BR>12. Sonal Matto - Non-Executive & Independent Director<BR>13. Ambrish Mithal - Independent Director<BR><BR>This team encompasses a mix of executive and non-executive roles, contributing to the governance and strategic direction of the company.

What is the bonus history of the Poly Medicure?

Poly Medicure has a history of issuing 1:1 bonus shares, with the most recent being on March 24, 2017. Previous bonuses were issued on July 9, 2013, and March 26, 2010, demonstrating the company's commitment to rewarding shareholders.

Poly Medicure has a history of issuing bonuses to its shareholders. The most recent bonus was a 1:1 bonus issue announced with an ex-date of March 24, 2017, and the record date was March 28, 2017. Prior to that, the company also issued a 1:1 bonus on July 9, 2013, with a record date of July 10, 2013. Additionally, there was another 1:1 bonus issued on March 26, 2010, with a record date of March 29, 2010. This consistent approach to issuing bonuses reflects the company's commitment to rewarding its shareholders.

Has Poly Medicure declared dividend?

Poly Medicure Ltd has declared a 60% dividend, amounting to ₹3 per share, with an ex-date of September 19, 2024. While the last 6 months showed a price decline of 20.81%, the company has demonstrated strong long-term growth, with total returns of 676.37% over the past 5 years.

Poly Medicure Ltd has declared a 60% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 60%<BR>- Amount per share: 3 per share<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -20.81%, with a dividend return of 0%, resulting in a total return of -20.81%.<BR><BR>Over the past year, the price return was 22.6%, the dividend return was 0.16%, leading to a total return of 22.76%.<BR><BR>In the 2-year period, the price return was 131.39%, with a dividend return of 0.52%, culminating in a total return of 131.91%.<BR><BR>For the 3-year period, the price return was 190.88%, the dividend return was 1.20%, resulting in a total return of 192.08%.<BR><BR>In the last 4 years, the price return was 123.05%, with a dividend return of 1.09%, leading to a total return of 124.14%.<BR><BR>Finally, over the past 5 years, the price return was 672.64%, the dividend return was 3.73%, resulting in a total return of 676.37%.<BR><BR>Overall, Poly Medicure has declared a significant dividend, and while the recent 6-month performance shows a decline, the longer-term returns over 1 to 5 years indicate strong growth, particularly in price returns.

Who are the peers of the Poly Medicure?

Poly Medicure's peers include Syngene Intl., Dr Lal Pathlabs, Indegene, Vijaya Diagnost., Metropolis Health, Thyrocare Tech., Suven Life Sciences, Laxmi Dental, Vimta Labs, and Krsnaa Diagnost. In terms of management risk, growth, and capital structure, they vary from excellent to below average, with Suven Life Sciences showing the highest 1-year return at 160.99% and Metropolis Health the lowest at -11.47%.

Peers: The peers of Poly Medicure are Syngene Intl., Dr Lal Pathlabs, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Suven Life Scie., Laxmi Dental, Vimta Labs, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and the rest. Below Average management risk is present at Suven Life Scie. and Krsnaa Diagnost. Growth is classified as Good at Laxmi Dental, Average at Poly Medicure, Indegene, and the rest, while Below Average growth is noted for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Suven Life Scie. Excellent capital structure is seen at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Good capital structure is found at Laxmi Dental, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 160.99%, while the lowest is Metropolis Healt at -11.47%. Poly Medicure's 1-year return of 24.29% is significantly higher than Metropolis Healt's but lower than Suven Life Scie.'s. Additionally, the peers with negative six-month returns include Syngene Intl., Metropolis Healt, and Krsnaa Diagnost.

Is Poly Medicure overvalued or undervalued?

As of August 29, 2022, Poly Medicure is considered very expensive and overvalued, with a PE Ratio of 66.70 and other high valuation metrics, despite a strong one-year return of 24.52%.

As of 29 August 2022, the valuation grade for Poly Medicure moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued based on its high valuation metrics. Key ratios include a PE Ratio of 66.70, an EV to EBITDA of 47.56, and a Price to Book Value of 8.17, all of which suggest that the stock is trading at a premium compared to its earnings and assets.<BR><BR>In comparison to peers, Poly Medicure's PE Ratio is notably higher than Blue Jet Health's 51.29 and Vimta Labs' 34.32, both of which are also categorized as expensive or very expensive. The PEG Ratio of 2.76 further underscores the overvaluation, especially when juxtaposed with more attractively valued companies like Raaj Medisafe, which has a PEG Ratio of 0.33. Despite a strong one-year return of 24.52% against the Sensex's 7.62%, the overall valuation metrics indicate that Poly Medicure is overvalued in the current market environment.

What does Poly Medicure do?

Poly Medicure Ltd is a large-cap manufacturer of medical devices, reporting net sales of ₹4,408 Cr and a net profit of ₹918 Cr for the quarter ending March 2025. The company, incorporated in 1995, has a market cap of ₹21,902 Cr and key metrics including a P/E ratio of 63.00 and a dividend yield of 0.14%.

Overview:<BR>Poly Medicure Ltd is a manufacturer of medical devices operating in the healthcare services industry and is categorized as a large-cap company.<BR><BR>History:<BR>Poly Medicure Limited was incorporated on March 30, 1995. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 4,408 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 918 Cr (Quarterly Results - Mar 2025) <BR>Market-cap: INR 21,902 Cr (Large Cap) <BR><BR>Key Metrics:<BR>P/E: 63.00 <BR>Industry P/E: 53 <BR>Dividend Yield: 0.14% <BR>Debt Equity: -0.37 <BR>Return on Equity: 12.24% <BR>Price to Book: 7.98 <BR><BR>Contact Details:<BR>Address: Property No 232B 3rd Floor, Okhla Indl Estate Phase-III New Delhi New Delhi : 110020 <BR>Tel: 91-11-26321838/81/89/93 <BR>Email: investorcare@polymedicure.com <BR>Website: http://www.polymedicure.com

Who are the top shareholders of the Poly Medicure?

The top shareholders of Poly Medicure include promoters, with Ezekiel Global Business Solutions LLP holding 12.2%, and institutional investors, including 21 mutual fund schemes with 7.16% and 171 foreign institutional investors with 11.46%. Individual investors own 11.08%, with Quant Mutual Fund being the largest public shareholder at 3.35%.

The top shareholders of Poly Medicure include a mix of promoters, institutional investors, and individual investors. The majority shareholders are the promoters, with Ezekiel Global Business Solutions LLP holding the highest stake at 12.2%. <BR><BR>In terms of institutional holdings, 21 mutual fund schemes collectively hold 7.16%, while 171 foreign institutional investors (FIIs) account for 11.46% of the shares. The highest public shareholder is Quant Mutual Fund, specifically the Quant Small Cap Fund, which holds 3.35%. Additionally, individual investors collectively own 11.08% of the company.

How has been the historical performance of Poly Medicure?

Poly Medicure has shown consistent growth, with net sales increasing from 610.83 Cr in Mar'19 to 1,669.83 Cr in Mar'25, and profit after tax rising from 64.00 Cr to 333.38 Cr. The company has also strengthened its balance sheet, eliminating long-term borrowings and significantly increasing total assets and shareholder's funds.

Answer:<BR>The historical performance of Poly Medicure shows a consistent growth trajectory in net sales, with figures rising from 610.83 Cr in Mar'19 to 1,669.83 Cr in Mar'25. The total operating income has followed a similar upward trend, reaching 1,669.83 Cr in Mar'25, compared to 610.83 Cr in Mar'19. Operating profit has also increased significantly, with the operating profit (PBDIT) rising from 147.72 Cr in Mar'19 to 541.97 Cr in Mar'25. Profit before tax has shown a robust increase from 98.67 Cr in Mar'19 to 447.34 Cr in Mar'25, while profit after tax has grown from 64.00 Cr to 333.38 Cr over the same period. The company's earnings per share (EPS) have improved from 7.41 in Mar'19 to 33.41 in Mar'25, reflecting strong profitability growth. <BR><BR>In terms of balance sheet metrics, total assets have surged from 767.32 Cr in Mar'20 to 3,192.13 Cr in Mar'25, indicating significant expansion. Shareholder's funds have also increased markedly from 434.82 Cr in Mar'20 to 2,765.66 Cr in Mar'25. The company has reduced its long-term borrowings to zero by Mar'25, down from 110.57 Cr in Mar'20, showcasing a strong financial position. Cash flow from operating activities has improved, reaching 266.00 Cr in Mar'24, while the closing cash and cash equivalents increased from 4.00 Cr in Mar'20 to 12.00 Cr in Mar'24. Overall, Poly Medicure has demonstrated strong growth in revenue, profitability, and asset base over the years.<BR><BR>Breakdown:<BR>Poly Medicure's financial performance has shown remarkable growth over the years, with net sales increasing from 610.83 Cr in Mar'19 to 1,669.83 Cr in Mar'25. This growth is mirrored in total operating income, which reached 1,669.83 Cr in Mar'25, up from 610.83 Cr in Mar'19. Operating profit (PBDIT) has also seen significant growth, climbing from 147.72 Cr in Mar'19 to 541.97 Cr in Mar'25, while profit before tax rose from 98.67 Cr to 447.34 Cr in the same period. Profit after tax increased from 64.00 Cr to 333.38 Cr, and earnings per share improved from 7.41 to 33.41, indicating strong profitability. On the balance sheet, total assets surged from 767.32 Cr in Mar'20 to 3,192.13 Cr in Mar'25, with shareholder's funds rising from 434.82 Cr to 2,765.66 Cr. The company eliminated long-term borrowings, achieving a zero balance by Mar'25, and cash flow from operating activities improved to 266.00 Cr in Mar'24, with closing cash and cash equivalents increasing to 12.00 Cr. Overall, Poly Medicure has exhibited substantial growth in revenue, profit, and financial stability.

Is Poly Medicure technically bullish or bearish?

As of November 10, 2025, Poly Medicure's technical trend is bearish with moderate strength, supported by daily moving averages and Bollinger Bands, despite mixed signals from the MACD across different time frames.

As of 10 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Poly Medicure is bearish with moderate strength. Key indicators driving this stance include the daily moving averages indicating a bearish trend, and both the weekly and monthly Bollinger Bands also confirming bearish conditions. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly, indicating mixed signals across time frames. Additionally, the Dow Theory supports a mildly bearish outlook on both weekly and monthly bases. Overall, the bearish trend is reinforced by the recent price action, with a significant decline in stock performance compared to the Sensex over multiple time frames.

When is the next results date for Poly Medicure Ltd?

The next results date for Poly Medicure Ltd is 05 February 2026.

The next results date for Poly Medicure Ltd is scheduled for 05 February 2026.

Are Poly Medicure Ltd latest results good or bad?

Poly Medicure Ltd's latest Q3 FY26 results show mixed performance; while revenue grew by 16.37% to ₹493.66 crores, net profit fell by 16.78% to ₹70.93 crores, and operating margins decreased to 22.52%. Overall, these trends indicate challenges in profitability and operational efficiency, suggesting the results are not favorable for investors.

Poly Medicure Ltd's latest results for Q3 FY26 present a mixed picture, but overall, they lean towards the negative side. While the company reported a revenue growth of 16.37% year-on-year, reaching ₹493.66 crores, the net profit fell significantly by 16.78% to ₹70.93 crores. This decline in profit is concerning, especially as it occurred despite the revenue increase.<BR><BR>Moreover, the operating margin has compressed to 22.52%, the lowest in seven quarters, indicating challenges in cost management and operational efficiency. Employee costs surged dramatically, up 51.13% year-on-year, which has further pressured profitability. The stock has also underperformed significantly, with a one-year decline of 39.31%, contrasting sharply with the Sensex's gain.<BR><BR>In summary, while revenue growth is a positive aspect, the decline in net profit, margin compression, and overall operational challenges suggest that the latest results are not favorable for Poly Medicure Ltd. Investors may need to be cautious given these trends.

Should I buy, sell or hold Poly Medicure Ltd?

Why is Poly Medicure Ltd falling/rising?

As of 17-Mar, Poly Medicure Ltd's stock price is Rs 1,241.30, down 1.24% and on a downward trend for four consecutive days, with a total decline of 6.77%. The stock has significantly underperformed, with a year-to-date drop of 30.10% and a 44.00% decline over the past year, indicating poor long-term growth prospects.

As of 17-Mar, Poly Medicure Ltd's stock price is falling, currently at Rs 1,241.30, which reflects a decrease of Rs 15.6 or 1.24%. The stock has been on a downward trend, having lost value for four consecutive days, resulting in a total decline of 6.77% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>The stock's performance over various time frames also highlights its struggles; it has declined by 30.10% year-to-date and a significant 44.00% over the past year, while the benchmark Sensex has increased by 2.56% in the same period. Furthermore, Poly Medicure's recent results have shown negative indicators, including a drop in profit after tax by 11.0% and a low debtors turnover ratio, which is the lowest at 4.02 times.<BR><BR>Investor participation appears to be waning, as evidenced by a 45.15% drop in delivery volume compared to the 5-day average. The stock is also close to its 52-week low, just 2.49% away from Rs 1,210.35. These factors collectively contribute to the stock's decline, reflecting poor long-term growth prospects and underperformance relative to both the market and its peers.

Why is Poly Medicure Ltd falling/rising?

As of 18-Mar, Poly Medicure Ltd's stock price has increased by 3.2% after a trend reversal, reaching an intraday high of Rs 1293. However, despite this short-term gain, the stock has significantly underperformed over the year, with a 27.86% year-to-date decline and a bearish overall trend.

As of 18-Mar, Poly Medicure Ltd's stock price is rising, having increased by 39.7 points or 3.2%. This upward movement follows a trend reversal after four consecutive days of decline. The stock reached an intraday high of Rs 1293, reflecting a gain of 4.16% during the day. Additionally, the medical equipment sector, in which Poly Medicure operates, has shown positive performance, gaining 3.16%. <BR><BR>Despite this rise, the stock has been underperforming in the longer term, with a year-to-date decline of 27.86% and a one-year drop of 42.66%. The stock is currently trading below its moving averages across various time frames, indicating a bearish trend overall. Furthermore, there has been a decrease in investor participation, with delivery volume falling by 14.72% compared to the five-day average. <BR><BR>While the company has a low debt-to-equity ratio and high institutional holdings, which can be seen as positive factors, the poor long-term growth and negative financial results, such as a decline in PAT and low operating profit margins, contribute to a mixed outlook. Therefore, while the stock is experiencing a short-term rise, its long-term performance remains concerning.

Why is Poly Medicure Ltd falling/rising?

As of 19-Mar, Poly Medicure Ltd's stock price is at 1,253.20, down 2.03%, and has fallen 44.44% over the past year, significantly underperforming the BSE500 index. The stock is trading below its moving averages, indicating a bearish trend, and despite some positive indicators, overall sentiment remains negative due to modest growth and high valuation ratios.

As of 19-Mar, Poly Medicure Ltd's stock price is falling, currently at 1,253.20, reflecting a decrease of 26.0 points or 2.03%. This decline is part of a broader trend, as the stock has experienced a significant drop of 44.44% over the past year, which is substantially worse than the BSE500 index, which has only declined by 1.65% in the same period. <BR><BR>The stock's performance has been underwhelming in the short term as well, with a 4.33% decrease over the past week and a 2.00% decline over the past month. Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend. <BR><BR>Today, the stock reached an intraday low of Rs 1231.45, down 3.73%, and is close to its 52-week low, being only 3.42% away from Rs 1210.35. The medical equipment sector, to which Poly Medicure belongs, has also faced a downturn, falling by 3.07%. <BR><BR>Despite some positive indicators, such as rising investor participation with a 27.95% increase in delivery volume, the overall sentiment remains negative due to poor long-term growth prospects. The company's operating profit growth has been modest at an annual rate of 17.77% over the last five years, and recent financial results have shown a decline in profit after tax by 11.0%. <BR><BR>Moreover, the stock's high Price to Book Value ratio of 4.4 suggests it is considered expensive compared to its peers, which may deter potential investors. These factors collectively contribute to the stock's current downward trajectory.

Why is Poly Medicure Ltd falling/rising?

As of 20-Mar, Poly Medicure Ltd's stock price is Rs 1,241.60, reflecting a slight increase of 0.47%. However, the stock has experienced significant long-term declines of 30.08% year-to-date and 44.18% over the past year, indicating a bearish trend and waning investor interest.

As of 20-Mar, Poly Medicure Ltd's stock price is rising slightly, with a current price of Rs 1,241.60, reflecting a change of 5.75 (0.47%) upward. Despite this minor increase, the stock has shown a significant decline over the longer term, with a year-to-date drop of 30.08% and a one-year decline of 44.18%. <BR><BR>The stock's performance today is inline with the sector, and it reached an intraday high of Rs 1,276.75, which is a 3.31% increase. However, it is important to note that the stock is trading lower than its moving averages across various time frames, indicating a bearish trend. Additionally, investor participation has decreased, with a delivery volume that has fallen by 12.04% compared to the 5-day average, suggesting waning interest among investors.<BR><BR>While the company has a low debt-to-equity ratio and high institutional holdings at 23.24%, which may provide some stability, the overall outlook remains negative due to poor long-term growth metrics. The operating profit has only grown at an annual rate of 17.77% over the last five years, and recent financial results have shown a decline in profit after tax and other key performance indicators. The stock's performance has been below par both in the near term and long term, contributing to its overall downward trajectory despite the slight rise observed today.

Why is Poly Medicure Ltd falling/rising?

As of 23-Mar, Poly Medicure Ltd's stock price is declining, currently at 1,204.25, reflecting a significant drop over various periods and hitting a new 52-week low. The stock's bearish trend is supported by negative financial indicators and challenges within the medical equipment sector.

As of 23-Mar, Poly Medicure Ltd's stock price is falling, currently at 1,204.25, which reflects a decrease of 37.35 (-3.01%). This decline is evidenced by the stock's performance over various periods, showing a 1-week drop of 4.19%, a 1-month decrease of 4.98%, and a significant year-to-date decline of 32.19%. Over the past year, the stock has experienced a substantial fall of 47.58%, while the broader market, represented by the Sensex, has only declined by 5.47% during the same timeframe.<BR><BR>Today, the stock hit a new 52-week low of Rs. 1195.65, indicating ongoing downward pressure. Additionally, Poly Medicure is trading below its moving averages across multiple timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. The medical equipment sector, in which Poly Medicure operates, has also faced challenges, with a sector decline of 3.49%.<BR><BR>Despite a slight increase in investor participation, with delivery volume rising by 2.41% against the 5-day average, the overall sentiment remains negative. The company's financial performance has raised concerns, particularly with a reported decline in operating profit and a low debt-to-equity ratio, which, while average, does not inspire confidence in long-term growth. Furthermore, the stock's high price-to-book value ratio of 4.2 suggests it may be overvalued compared to its peers, contributing to the bearish outlook.<BR><BR>In summary, the combination of poor recent performance, negative financial indicators, and broader sector challenges are key factors driving the decline in Poly Medicure Ltd's stock price.

Why is Poly Medicure Ltd falling/rising?

As of 24-Mar, Poly Medicure Ltd's stock price is rising to 1,240.00, up 2.97%. This increase is driven by positive trading momentum and higher investor participation, but the stock faces long-term challenges with a year-to-date decline of 30.17%.

As of 24-Mar, Poly Medicure Ltd's stock price is rising, currently at 1,240.00, reflecting an increase of 35.75 (2.97%). This upward movement can be attributed to several factors. Firstly, the stock opened with a gain of 3.6% today and reached an intraday high of Rs 1,256.35, indicating positive trading momentum. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 16.88% against the 5-day average, suggesting growing interest among investors.<BR><BR>Moreover, the broader sector of Medical Equipment/Supplies/Accessories has gained by 2.57%, which may also be contributing to the positive sentiment surrounding Poly Medicure. However, it is important to note that despite today's rise, the stock has been underperforming in the longer term, with a year-to-date decline of 30.17% and a one-year return of -46.39%. The stock is also trading below its moving averages, which typically indicates a bearish trend.<BR><BR>In summary, while Poly Medicure Ltd is experiencing a rise in its stock price today, this is occurring against a backdrop of significant long-term challenges, including poor growth metrics and underperformance relative to benchmarks.

Why is Poly Medicure Ltd falling/rising?

As of 25-Mar, Poly Medicure Ltd's stock price is rising to 1,303.20, up 4.81% today, with a two-day total return of 8.22%. This positive momentum is driven by sector gains, increased investor participation, and strong institutional support, despite long-term declines.

As of 25-Mar, Poly Medicure Ltd's stock price is rising, currently at 1,303.20, reflecting a change of 59.75 (4.81%) upward. The stock has outperformed its sector by 0.66% today and has shown a consecutive gain over the last two days, accumulating a total return of 8.22% during this period. Additionally, the stock reached an intraday high of Rs 1335, marking a rise of 7.36%.<BR><BR>The positive momentum can be attributed to several factors. The medical equipment sector has gained by 4.23%, contributing to the favorable environment for Poly Medicure Ltd. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 8.84% against the five-day average, indicating growing interest in the stock. The company's low debt-to-equity ratio and high institutional holdings at 23.24% suggest a stable financial position and confidence from larger investors, which can positively influence stock performance.<BR><BR>Despite the stock's recent gains, it is important to note that it has faced challenges in the long term, with a year-to-date decline of 26.61% and a one-year return of -41.06%. However, the current upward trend reflects short-term positive developments and market conditions that are favoring the stock at this moment.

Which are the latest news on Poly Medicure?